NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
5 trialsNCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00612066 2020-08-06
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00178841 2016-02-17
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Vanderbilt University
Phase 2 Completed